CLINICAL TRIALS PROFILE FOR EXTINA

« Back to Dashboard

All Clinical Trials for EXTINA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00703846 ↗	STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2%	Completed	GlaxoSmithKline	Phase 4	2008-06-01	Extina (ketoconazole) Foam, 2% was approved for marketing in the United States (US) in June 2007. Extina foam is indicated for topical treatment of seborrheic dermatitis in immunocompetent patients 12 years of age and older. The approved dosing regimen is twice daily for 4 weeks. The treatment of recurrent seborrheic dermatitis demands a topical preparation that is safe for both short-term and chronic application. This study is being conducted in order to obtain long-term safety data on the use of Extina (ketoconazole) Foam, 2% in the treatment of seborrheic dermatitis.
NCT00703846 ↗	STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2%	Completed	Stiefel, a GSK Company	Phase 4	2008-06-01	Extina (ketoconazole) Foam, 2% was approved for marketing in the United States (US) in June 2007. Extina foam is indicated for topical treatment of seborrheic dermatitis in immunocompetent patients 12 years of age and older. The approved dosing regimen is twice daily for 4 weeks. The treatment of recurrent seborrheic dermatitis demands a topical preparation that is safe for both short-term and chronic application. This study is being conducted in order to obtain long-term safety data on the use of Extina (ketoconazole) Foam, 2% in the treatment of seborrheic dermatitis.
NCT01203189 ↗	Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo	Completed	St. Louis University	N/A	2010-09-01	The aims of this study are to compare the effectiveness of antifungal foam versus antifungal shampoo and determine patient compliance and satisfaction with both vehicles among African American females with dandruff practicing less than once weekly hair washing.

Clinical Trial Conditions for EXTINA

Condition Name

Condition Name for EXTINA
Intervention	Trials
Dermatitis, Seborrheic	1
Seborrheic Dermatitis	1

Condition MeSH

Condition MeSH for EXTINA
Intervention	Trials
Dermatitis, Seborrheic	2
Dermatitis	2

Clinical Trial Locations for EXTINA

Trials by Country

Trials by Country for EXTINA
Location	Trials
United States	12

Trials by US State

Trials by US State for EXTINA
Location	Trials
Missouri	1
Virginia	1
Texas	1
Rhode Island	1
Oregon	1

Clinical Trial Progress for EXTINA

Clinical Trial Phase

Clinical Trial Phase for EXTINA
Clinical Trial Phase	Trials
Phase 4	1
N/A	1

Clinical Trial Status

Clinical Trial Status for EXTINA
Clinical Trial Phase	Trials
Completed	2

Clinical Trial Sponsors for EXTINA

Sponsor Name

Sponsor Name for EXTINA
Sponsor	Trials
GlaxoSmithKline	1
Stiefel, a GSK Company	1
St. Louis University	1

Sponsor Type

Sponsor Type for EXTINA
Sponsor	Trials
Industry	2
Other	1